PDCD1 and neoplasm: In a clinical trial (ChiCTR2100046768) focusing on patients with microsatellite stable metastatic colorectal cancer (MSS-mCRC), investigators implemented a triple therapy regimen combining FMT with PD-1 inhibitors and vascular endothelial growth factor receptor (VEGFR) inhibitors.31 Preliminary results suggested that this innovative triple therapy regimen effectively mitigated tumor progression, significantly decreased serum tumor marker levels, augmented patient immune function, and facilitated a balanced state of the gut microbiota.